The insulin pump market - France

The global insulin pump market, valued at US$5.67 billion in 2022, is expected to grow at a CAGR of 8.8%, reaching US$9.4 billion by 2028. Driven by a sharp rise in the prevalence of diabetes worldwide, particularly in regions such as Africa, Asia-Pacific and the Middle East, this market is experiencing significant growth.In 2021 alone, the global diabetes population grew by 74 million to 537 million, with forecasts of 643 million by 2030 and 783 million by 2045. In Asia-Pacific, the Middle East, North Africa and Africa, the diabetic population could more than double by 2045 compared with 2021.

The French market, with an average annual growth rate of 6.58%, and spending such as the 9,576 million euros allocated to diabetes care by the French health insurance system in 2021, reflect the robust dynamics of this sector. Innovations and the introduction of advanced insulin pump models, such as Medtronic's Minimed 780G, Omnipod DASH and Tandem's t:slim X2, meet the needs of an increasingly aware diabetic population. Despite a diverse market landscape, major entities like Medtronic, Roche and others dominate the scene, focusing on connected technologies and more patient-friendly solutions to improve diabetes management.

Insulin pump market trends and dynamics in France

The French insulin pump market is demonstrating considerable dynamism and growth potential, being one of the leading consumers of diabetes treatments in Europe. While the value of the global market is set to increase, with estimates reaching between US$5 and US$10 billion by 2028, France reflects this momentum with a CAGR of around 6-7% between 2023 and 2028.

France faces major challenges in diabetes care, with around 3 to 4 million people being treated, and an alarming estimate that almost a million French citizens are undiagnosed. Despite a slight drop in 2020, the number of people receiving care has again risen substantially, reaching over 4 million in 2021. Notably, type 2 diabetes dominates the landscape, accounting for 92% of cases, with type 1 and other rarer forms making up the remainder. Those most affected are the over-65s, who account for over 60% of the diabetic population, with men slightly outnumbering women in terms of prevalence. Territorial disparities within France reveal that regions such as the French overseas departments and areas like Hauts-de-France and Grand-Est have higher prevalence rates than the national average. Diabetes also coincides with co-morbidities such as cardiovascular disease, psychotropic medication use, cancer and chronic respiratory conditions.

A significant trend in insulin pump use in France indicates that while almost 860,000 people are on insulin therapy, only 2-5% of diabetics use insulin pump technology, compared with 25% in the USA. However, this landscape is changing with the steady increase in insulin pump adoption among French diabetics. The number of users has increased almost fourfold to 82,000. Market expansion is also being driven by health insurance reimbursements, which play a central role in the accessibility of these devices. Such growth indicates an increasing trend in pump use, further amplified by the inclusion of new models such as the Minimed™ 780G, Omnipod DASH™.

Key manufacturers dominating the insulin pump landscape

The constantly evolving insulin pump market is driven by leading manufacturers who have established formidable positions within the healthcare industry, due to their in-depth expertise, innovative technologies and extensive range of products meeting the diverse needs of diabetic patients. Below are the main players who have made significant advances in the insulin pump market:

• Medtronic Medtronic is a pioneer in medical technology, particularly in the field of insulin pumps. The company boasts a solid product range that is well received the world over. Among its flagship products, the MiniMed 640G represents Medtronic's commitment to advanced diabetes management solutions. Although the company has decided to cease production of internally implanted insulin pumps, it continues to influence the market with its external devices and is recognized for its contribution to the evolution of modern diabetes care.
• Roche is a pillar of the insulin pump market under the banner of its Accu-Chek brand, known for its reliability and precision. Despite fierce competition from specialists such as Medtronic and Abbott, Roche continues to innovate, striving to breathe new life into its offerings in the diabetes sector. The company is seeking to establish itself in the market by launching products such as the Eversense continuous glucose monitor, building on the success of its flagship products, the Accu-Chek Insight and Accu-Chek Spirit Combo.
• Insulet is renowned for its revolutionary Omnipod device, which challenges traditional pump designs with its tubeless patch, enabling simplified management and three days of continuous insulin delivery. This approach has brought a new level of comfort and convenience to insulin pump users, and positioned Insulet as a key player intent on reshaping diabetes treatment.
• Ypsomed made its mark on the market with the myLife Ypsopump, an intuitive, connected pump with a user-friendly interface. Its clear commitment to marrying technology with patient-friendliness makes Ypsomed a reference name for those seeking modern treatment tools.
• Cellnovo Although smaller than the other players, Cellnovo continues to attract attention with its unique range of insulin pumps, including the Gen 3 and Gen 2 models. Known for pushing the boundaries of design and functionality, Cellnovo appeals to a niche segment that values innovation and user-centric features in diabetes treatment.

These key players have helped shape the landscape of the insulin pump market, each bringing their own distinct perspectives and specialist knowledge

Inforamtion

• Number of pages : 30 pages
• Format : Digital and PDF versions
• Last update : 10/10/2023

Summary and extracts

List of charts

• Insulin pump market size
• Distribution of the number of diabetics by world region
• Distribution of diabetics by world region
• Growth in the number of diabetics worldwide
• Countries with the highest number of diabetics
• People treated for diabetes (types 1 and 2)
• Breakdown of the proportion of diabetics by sex
• Distribution of the proportion of diabetics
• Proportion of diabetics by type of diabetes
• Number of people treated for diabetes by age group and sex
• Among people managed for diabetes, percentage of people with at least...
• Trends in obesity and overweight in the French population
• Trends in obesity in the population by gender
• Overweight and obesity by age
• Percentage of overweight and obese people in different occupational categories
• Expenditure reimbursed by the Assurance Maladie for diabetes
• Breakdown of diabetes-related expenditure
• Average reimbursed expenses per diabetic patient
• Market share of diabetes treatments
• Market share of diabetes treatments
• Sales of Medtronic's diabetes division
• Diabetes-related healthcare expenditure in France